Pregabalin in the management of partial epilepsy

doi:10.2147/NDT.S3850

Paper

Pregabalin in the management of partial epilepsy

Published Jul 31, 2009 · A. Arain

Neuropsychiatric Disease and Treatment

Q2 SJR score

14

Citations

1

Influential Citations

Full textSemantic Scholar

Abstract

Pregabalin is a new antiepileptic medication that works by binding to alpha 2 delta subunit of the voltage-dependent calcium channels present in presynaptic neurons. Its pharmacokinetic advantages include rapid and almost complete absorption, lack of protein binding, linear kinetics, absence of enzyme induction, and absence of interactions with other drugs. Pregabalin was found effective as adjunctive therapy for refractory partial-onset seizures, with up to 51% responder at a dose of 600 mg/day. The lowest effective dose was 150 mg/day. Pregabalin is also approved for treatment of painful diabetic polyneuropathy, postherpetic neuralgia and pain with fibromyalgia. Studies also suggest a beneficial effect on sleep and generalized anxiety disorders. Its main adverse effects in randomized adjunctive trials in adults have been mild to moderate. Most common side effects were dizziness, ataxia, somnolence and diplopia. Weight gain was not prominent in pivotal pregabalin trials, but was more problematic in long-term postmarketing analyses in epilepsy patients. Pregabalin, with its potent antiseizure effect, favorable pharmacokinetic profile, and effectiveness in common co-morbidities is an important addition to the treatment of epilepsy.

Rigorous Journal

Study Snapshot

Pregabalin effectively treats partial epilepsy and common co-morbidities, with mild to moderate side effects and potential benefits for sleep and anxiety disorders.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Pregabalin in the management of partial epilepsy

Sign up to use Study Snapshot

References

Add-on treatment with pregabalin for partial seizures with or without generalisation: Pooled data analysis of four randomised placebo-controlled trials

Pregabalin add-on treatment significantly reduces seizure frequency and has good tolerability in treatment-resistant partial seizures patients.

Pregabalin for the management of partial epilepsy

Pregabalin is an effective and safe adjunctive therapy for refractory partial epilepsy, with a clear dose-response relationship and improved tolerability when dosed individualized.

Adjunctive pregabalin therapy in mentally retarded, developmentally delayed patients with epilepsy

Adjunctive pregabalin therapy effectively reduces seizure frequency in mentally retarded, developmentally delayed patients with epilepsy, but may cause weight gain, myoclonus, and sedation.

Efficacy and tolerability of pregabalin in patients with difficult-to-treat epilepsy and intellectual disability

Pregabalin showed moderate efficacy in patients with therapy-resistant epilepsy and intellectual disability, but its tolerability was limited by common side effects.

Efficacy and tolerability of pregabalin in partial epilepsy

Pregabalin is an effective and well-tolerated antiepileptic drug for partial-onset seizures, with dose-dependent adverse events.

Bodyweight gain under pregabalin therapy in epilepsy: Mitigation by counseling patients?

Pregabalin treatment for epilepsy is associated with a high risk of bodyweight gain, which cannot be prevented by extended patient counseling in a standard clinical setting.

A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia.

Pregabalin at 300, 450, and 600 mg/day is effective and safe for treating pain associated with fibromyalgia, providing clinically meaningful benefit to patients.

Serum Concentrations of Pregabalin in Patients With Epilepsy: The Influence of Dose, Age, and Comedication

Pregabalin serum concentrations are lower in combination with enzyme-inducing antiepileptic drugs and higher in older patients, with comedication slightly affecting PGB levels.

Citations

Anxiety Disorders in Epilepsy

Anxiety disorders are common psychiatric comorbidities in patients with epilepsy, with varying relationships to different forms of epilepsy, demographics, and epileptic focus.

Conversion of Pregabalin to 4-Isobutylpyrrolidone-2.

Pregabalin can be converted to 4-isobutylpyrrolidone-2 through a combination of experimental and quantum chemical methods.

Development and Validation of Stability Indicating RP-HPLC method for simultaneous estimation of Epalrestat and Pregabalin in bulk and tablet dosage form

The developed stability-indicating RP-HPLC method is a sensitive, precise, and accurate method for estimating Epalrestat and Pregabalin in bulk and tablet dosage forms, with no interference from excipients.

Monitoring of Pregabalin in Pharmaceutical Formulations and HumanSerum Using UV and RP-HPLC Techniques: Application to DissolutionTest Method

The developed method is a sensitive, efficient, and environmentally friendly method for determining pregabalin in pharmaceutical formulations and human serum, with good precision and accuracy.

The potential of pregabalin in neurology, psychiatry and addiction: a qualitative overview.

Pregabalin may help reduce pain in various conditions, treat seizures, and potentially treat anxiety disorders and alcohol abuse.

Pregabalin’s effect on human genetic material: in vitro study

Pregabalin at therapeutic doses increases sister chromatid exchange frequencies and diminishes proliferation rate index in normal human lymphocyte cultures, suggesting potential genotoxic effects.

Costs, work absence, and adherence in patients with partial onset seizures prescribed gabapentin or pregabalin

Pregabalin users for partial onset seizures have lower overall costs, fewer sick leave days, and higher adherence rates compared to gabapentin users.

Changes in seizure severity and quality of life in patients with refractory partial epilepsy

Reducing seizure severity with appropriate medication may improve the overall quality of life for patients with refractory partial epilepsy.

Antiepileptic Drug-Related Ataxia in Children

Ataxia in children can be a challenging clinical sign related to the use of second and third generation anticonvulsants, with potential genetic and acquired causes.